Skip to main content
Terug
GHRS logo

GH Research PLC

Datakwaliteit: 100%
GHRS
NASDAQ Healthcare Biotechnology
€ 13,39
▲ € 0,18 (1,36%)
Marktkapitalisatie: 830,57M
Dagbereik
€ 12,77 € 13,53
52-Weeksbereik
€ 7,98 € 19,51
Volume
101.676
50D / 200D Gem.
€ 15,62 / € 14,17
Vorige Slotkoers
€ 13,21

Koershistorie

Financiële Trends

Sectorvergelijking

vs Healthcare sector mediaan (627 peers)

Metriek Aandeel Sector Mediaan
P/E -17,2 0,3
P/B 3,0 2,9
ROE % -21,0 3,7
Net Margin % 3,8
Rev Growth 5Y % 10,0
D/E 0,0 0,2

Koersdoel Analisten

Hold
€ 36,50 +172.6%
Low: € 32,00 High: € 40,00
Forward WPA
-€ 1,46
Omzet Sch.
0

Winstschattingen

Periode WPA Sch. Omzet Sch. Analisten
FY2030 € 0,17
€ 0,17 – € 0,17
350 M 5
FY2029 -€ 1,60
-€ 1,60 – -€ 1,60
91 M 2
FY2028 -€ 2,18
-€ 3,34 – -€ 1,54
5,1 M 7

Belangrijkste Punten

Debt/Equity of 0,00 — conservative balance sheet
Negative free cash flow of -43,67M

Groei

Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Kwaliteit

Return on Equity
-21,04%
ROIC-16,24%
Net MarginN/A
Op. MarginN/A

Veiligheid

Debt / Equity
0,00
Current Ratio34,13
Interest Coverage-131,05

Waardering

P/E Ratio
-17,21
P/B Ratio2,97
EV/EBITDAN/A
Dividend Yield0,00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) N/A Revenue Growth (3Y) N/A
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 0,0 Net Income (TTM) -48,26M
ROE -21,04% ROA -16,74%
Gross Margin N/A Operating Margin N/A
Net Margin N/A Free Cash Flow (TTM) -43,67M
ROIC -16,24% FCF Growth (3Y) N/A
Safety
Debt / Equity 0,00 Current Ratio 34,13
Interest Coverage -131,05 Dividend Yield 0,00%
Valuation
P/E Ratio -17,21 P/B Ratio 2,97
P/S Ratio N/A PEG Ratio -3,01
EV/EBITDA N/A Dividend Yield 0,00%
Market Cap 830,57M Enterprise Value 584,83M

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 0,0 0,0 0,0 0,0 0,0
Net Income -48,26M -38,96M -35,59M -22,46M -9,20M
EPS (Diluted) -0,79 -0,75 -0,68 -0,14 -0,18
Gross Profit -335.000,0 0,0 0,0 0,0 0,0
Operating Income -60,68M -50,31M -41,22M -30,55M -15,10M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 288,23M 188,27M 226,30M 254,36M 279,92M
Total Liabilities 8,53M 9,32M 7,33M 4,55M 2,75M
Shareholders' Equity 279,70M 178,95M 218,97M 249,82M 277,18M
Total Debt 512.000,0 624.000,0 974.000,0 0,0 0,0
Cash & Equivalents 246,25M 100,79M 78,42M 165,96M 276,78M
Current Assets 285,98M 154,23M 164,09M 168,54M 279,84M
Current Liabilities 8,38M 8,95M 6,70M 4,55M 2,75M